Abstract
Ceftaroline is novel “fifth generation” cephalosporin with broad acitivity, most notably including penicillinase-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA). Ceftaroline is inactive against Pseudomonas spp, other gram-negative non-fermenters, anaerobes and other multidrug resistant organisms. Ceftaroline has been evaluated for complicated skin and soft tissue infections in phase three clinical trials, CANVAS 1 and 2, which demonstrated non-inferiority to vancomycin and aztreonam. Infections evaluated included cellulitis, abscess, and skin and soft tissue ulcers. Decreased efficacy was noted in patient with Enterococcus faecalis and Proteus mirabilis infections. Ceftaroline is well tolerated with a favorable safety profile, and may play an important role in the future treating serious MRSA-related infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
